Hawton K, Townsend E, Deeks J, Appleby L, Gunnell D, Bennewith O, Cooper J
Centre for Suicide Research, University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK.
BMJ. 2001 May 19;322(7296):1203-7. doi: 10.1136/bmj.322.7296.1203.
To evaluate the effects on suicidal behaviour of legislation limiting the size of packs of paracetamol and salicylates sold over the counter.
Before and after study.
UK population, with detailed monitoring of data from five liver units and seven general hospitals, between September 1996 and September 1999.
People who died by suicidal or accidental overdose with paracetamol or salicylates or who died of undetermined causes; patients admitted to liver units with hepatic paracetamol poisoning; patients presenting to general hospitals with self poisoning after taking paracetamol or salicylates.
Mortality from paracetamol or salicylate overdose; numbers of patients referred to liver units or listed for liver transplant; numbers of transplantations; numbers of overdoses and tablets taken; blood concentrations of the drugs; prothrombin times; sales to pharmacies and other outlets of paracetamol and salicylates.
Numbers of tablets per pack of paracetamol and salicylates decreased markedly in the year after the change in legislation on 16 September 1998. The annual number of deaths from paracetamol poisoning decreased by 21% (95% confidence interval 5% to 34%) and the number from salicylates decreased by 48% (11% to 70%). Liver transplant rates after paracetamol poisoning decreased by 66% (55% to 74%). The rate of non-fatal self poisoning with paracetamol in any form decreased by 11% (5% to 16%), mainly because of a 15% (8% to 21%) reduction in overdoses of paracetamol in non-compound form. The average number of tablets taken in paracetamol overdoses decreased by 7% (0% to 12%), and the proportion involving >32 tablets decreased by 17% (4% to 28%). The average number of tablets taken in salicylate overdoses did not decrease, but 34% fewer (2% to 56%) salicylate overdoses involved >32 tablets. After the legislation mean blood concentrations of salicylates after overdose decreased, as did prothrombin times; mean blood concentrations of paracetamol did not change.
Legislation restricting pack sizes of paracetamol and salicylates in the United Kingdom has had substantial beneficial effects on mortality and morbidity associated with self poisoning using these drugs.
评估限制非处方销售的对乙酰氨基酚和水杨酸盐包装规格的立法对自杀行为的影响。
前后对照研究。
1996年9月至1999年9月期间,对英国人群进行研究,并对来自5个肝病科和7家综合医院的数据进行详细监测。
因服用对乙酰氨基酚或水杨酸盐自杀或意外过量致死、死因不明者;因对乙酰氨基酚肝中毒入住肝病科的患者;服用对乙酰氨基酚或水杨酸盐后因自我中毒到综合医院就诊的患者。
对乙酰氨基酚或水杨酸盐过量导致的死亡率;转诊至肝病科或列入肝移植名单的患者数量;肝移植数量;过量服药及服用的药片数量;药物血药浓度;凝血酶原时间;对乙酰氨基酚和水杨酸盐在药店及其他销售点的销售量。
1998年9月16日立法变更后的一年里,每包对乙酰氨基酚和水杨酸盐的片数显著减少。对乙酰氨基酚中毒导致的年死亡人数下降了21%(可信区间95%:5%至34%),水杨酸盐中毒导致的年死亡人数下降了48%(11%至70%)。对乙酰氨基酚中毒后的肝移植率下降了66%(55%至74%)。任何形式的对乙酰氨基酚非致命性自我中毒发生率下降了11%(5%至16%),主要原因是非复方对乙酰氨基酚过量服药减少了15%(8%至21%)。对乙酰氨基酚过量服药时服用的平均片数下降了7%(0%至12%),服用超过32片的比例下降了17%(4%至28%)。水杨酸盐过量服药时服用的平均片数没有下降,但服用超过32片的水杨酸盐过量服药次数减少了34%(2%至56%)。立法实施后,水杨酸盐过量服药后的平均血药浓度下降,凝血酶原时间也下降;对乙酰氨基酚的平均血药浓度没有变化。
英国限制对乙酰氨基酚和水杨酸盐包装规格的立法对与使用这些药物自我中毒相关的死亡率和发病率产生了重大有益影响。